RBC Capital Markets thinks CSL is a bargain at current levels. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool ...

This ASX heavyweight has potential to deliver superior returns but is more volatile. CSL remains the crown jewel of the ASX healthcare sector. Its plasma therapies, vaccines, and biologics underpin a ...

The Australian sharemarket added 25.20 points or 0.29 per cent to 8,720.80, while the broader All Ordinaries gained 28.50 points or 0.32 per cent to 9,046.50. The technology sector advanced 1.72 per ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its ...

As an Amazon Associate, we earn from qualifying purchases. TweakTown may also earn commissions from other affiliate partners at no extra cost to you. For cross-platform compatibility, the Fanatec GT ...

CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy the phase 3-ready blood clotting specialist VarmX in return for $117 million upfront. Last month, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is also closing two ...

SYDNEY--Vaccine and blood-products company CSL on Tuesday unveiled a sweeping corporate restructure that will include spinning off its flu-vaccine unit Seqirus and cutting up to 15% of its staff.

The most hyped sim racing peripheral of all time – the Fanatec CSL DD wheel base and the CSL Pedals. Here’s our in-depth review, that also includes the CSL Pedals Tuning Kit and CSL DD Desk Clamp, to ...

CSL to downsize one-third of R&D division, AFR reports Company has not confirmed the number of job reductions Shares up 3% at over 6-week high July 15 (Reuters) - Australian biotech giant CSL Ltd (CSL ...